Open AccessThe use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients
Author(s) -
A. E. Karateev,
E. Yu. Polishchuk,
A. S. Potapova,
E. V. Matyanova,
А. С. Семашко,
А. O. Bobkova,
Е. С. Филатова,
V. N. Amirjanova,
С. И. Глухова,
E. G. Zotkin,
А. М. Лила
Publication year - 2022
Publication title -
naučno-praktičeskaâ revmatologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.137
H-Index - 9
eISSN - 1995-4492
pISSN - 1995-4484
DOI - 10.47360/1995-4484-2022-149-156
Subject(s) - medicine , rheumatoid arthritis , leflunomide , tofacitinib , abatacept , janus kinase , tocilizumab , incidence (geometry) , adalimumab , antirheumatic agents , methotrexate , hydroxychloroquine , disease , janus kinase inhibitor , antirheumatic drugs , pandemic , rituximab , covid-19 , infectious disease (medical specialty) , cytokine , physics , lymphoma , optics